Mark Fesler
3 weeks 3 days
This research is consistent with many other HRQOL studies by showing that this parameter is improved in patients with better disease control
Role of FDG PET in the staging of multiple myeloma - PubMed
18 F-Fluorodeoxyglucose (FDG) PET has been used for staging of hematologic malignancies for years. In multiple myeloma, this imaging modality can be used in many different scenarios, including initial staging, ..... see more
Health-related quality of life in patients with relapsed or refractory multiple myeloma: treatment with daratumumab, lenalidomide, and dexamethasone in the phase 3 POLLUX trial - PubMed
doi: 10.1111/bjh.17435. Online ahead of print. 1 Vejle Hospital and University of Southern Denmark, Vejle, Denmark. 2 National and Kapodistrian University of Athens School of Medicine, Athens, Greece. 3 Institut ..... see more
Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - PubMed
Despite improvements in therapy, approximately 5% of patients who undergo autologous stem cell transplantation (ASCT) experience early mortality (EM), death within 1 year of transplant (EM post-ASCT). Such patients tend ..... see more
Show More Comments
-
Mark Fesler 3 weeks 3 days
Death within a year of autoSCT not only indicates a disease resistant to chemo but also novel agents given the prolonged pfs of triplet regimens in salvage. These patients Show More
Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design - PubMed
Belantamab mafodotin (belamaf) is a BCMA-targeted antibody-drug conjugate recently approved as monotherapy for adults with relapsed/refractory multiple myeloma who have received ≥4 prior therapies. Belamaf binds to BCMA and eliminates ..... see more
Show More Comments
-
Mark Fesler 3 weeks 4 days
This antibody conjugate has intriguing efficacy in a population of patients that has few options ...
Antibody-Based Treatment Approaches in Multiple Myeloma - PubMed
Three monoclonal antibodies (daratumumab, isatuximab, elotuzumab) and one anti-BCMA (B-cell maturation antigen) antibody-drug conjugate (belantamab mafodotin) have been approved by the FDA in the last 5 years for the treatment ..... see more
Show More Comments
-
Mark Fesler 3 weeks 4 days
There are many more surface targets that have been identified in myeloma beyond cd38, slamf1, and bcma which is extremely exciting for the future of myeloma care
Autologous hematopoietic transplantation following COVID‐19 infection
Marthilde Brzycki, 1 Robert Richard, 1 , 2 Nicholas Burwick, 1 , 2 Solomon Graf, 1 , 3 , 4 Craig O'Brien, 1 Daniel Wu, 1 , 3 and Thomas ..... see more
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981617/
Show More Comments
-
Mark Fesler 3 weeks 4 days
An interesting report. More knowledge in this area is needed as clinicians presently face challenging decisions on balancing risks of malignancy and covid without a solid evidence base
FDA approves Sarclisa® (isatuximab-irfc) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa ® (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult ..... see more
Show More Comments
-
Mark Fesler 3 weeks 4 days
An expanded indication for a cd38 antibody, which are in key class of medications in the treatment of myeloma ...
Optic nerve head plasmacytoma as a manifestation of multiple myeloma - PubMed
Extramedullary disease in multiple myeloma is uncommon and associated with a poorer prognosis. Extramedullary disease involving the orbit is even more unusual, with optic nerve involvement being rare. We describe ..... see more
Show More Comments
-
Mark Fesler 3 weeks 4 days
The head and neck region seems to be a common site of extramedullary myeloma /plasmacytoma involvement for reasons that I’m not sure are well understood
FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma
The U.S. Food and Drug Administration approved Abecma (idecabtagene vicleucel), a cell-based gene therapy to treat adult patients with multiple myeloma who have not responded to, or whose disease has ..... see more
Show More Comments
-
Mark Fesler 1 month
This is a very exciting advance for the field of myeloma and ushers in a new era of treatment Existing treatment algorithms will require modification
Targeting SIRT1 to inhibit the proliferation of multiple myeloma cells - PubMed
Multiple myeloma (MM) is the second most common hematopoietic malignancy and remains an incurable disease. Thus, novel drugs and therapeutic methods are required for patients with MM. The present study ..... see more
2020 FDA TIDES (Peptides and Oligonucleotides) Harvest
2020 has been an extremely difficult and challenging year as a result of the coronavirus disease 2019 (COVID-19) pandemic and one in which most efforts have been channeled into tackling ..... see more
Source : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7918236/
Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma
AbstractBackground. Due to improved treatment, more patients with multiple myeloma (MM) reach a state of minimal residual disease (MRD). Different strategies fo see more
Source : https://academic.oup.com/clinchem/advance-article-abstract/doi/10.1093/clinchem/hvab017/6168671
miR‐17‐3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition
Kangdong Liu Corresponding Author China‐US (Henan) Hormel Cancer Institute, Zhengzhou, Henan, China Department of Pathophysiology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, Henan, China Cancer Chemoprevention International Collaboration Laboratory, ..... see more
Source : https://doi.org/10.1002/ijc.33528
63-Year-Old Female Experiences Slow Relapse
Evelyn, now 63, was diagnosed with multiple myeloma when she was 58. She is a district manager for her company and has .....
see more
Show More Comments
-
Mark Fesler 1 month 3 weeks
Elo or dara or kyprolis + rev or Pom + dex This is a situation I like elo to save bigger guns for a symptomatic relapse Could be Show More -
Sherif Badawy 1 month 3 weeks
Given what we know about safety and efficacy data as well as potential benefits for quality of life outcomes, adding Daratumumab and Dex would have potential clinical benefits as best Show More
Proteomics-Based Approach Reveals the Involvement of SERPINB9 in Recurrent and Relapsed Multiple Myeloma
Multiple myeloma (MM) is a common hematological malignancy with poorly understood recurrence and relapse mechanisms. Notably, bortezomib resistance leading to relapse makes MM treatment significantly challenging. To clarify the drug ..... see more
Source : https://pubs.acs.org/doi/abs/10.1021/acs.jproteome.1c00007
Latest Developments in Cellular Therapy for Multiple Myeloma - touchONCOLOGY
Multiple myeloma (MM) is a malignant clonal disorder of plasma cells in the bone marrow, and more than 32,000 new cases are expected in the USA each year.1 Many clinical ..... see more
Promising Anti-Mitochondrial Agents for Overcoming Acquired Drug Resistance in Multiple Myeloma
Multiple myeloma (MM) remains an incurable tumor due to the high rate of relapse that still occurs. Acquired drug resistance represents the most challenging obstacle to the extension of survival ..... see more
Approaches and Challenges in the Management of Multiple Myeloma in the Very Old: Future Treatment Prospects
The increasing incidence of geriatric patients with multiple myeloma has elevated concerns in clinical practice. While the introduction of novel therapeutic agents has substantially improved outcomes in younger patients with ..... see more
Source : https://www.frontiersin.org/articles/10.3389/fmed.2021.612696/full
Show More Comments
A nice comprehensive review of pet in plasma cell dyscrasias. Overall this modality has taken on an increasing important role in the care of these patients in the last Show More